New approaches in angiogenic targeting for colorectal cancer

Table 2 Completed trials for Bevacizumab with chemotherapy in metastatic CRC

REF	Regimen	Pts	RR (%)	P	PFS or TTP (mo)	P	OS (mo)	P
28	IFL	411	35	0.004	6.2	< 0.001	15.6	< 0.001
	IFL + BV	402	45		10.6		20.3
32	5-FU/LV	35	17	-	5.2	-	13.6	-
	5-FU/LV + BV-low	35	40	0.029	9	0.005	21.5	0.137
	5-FU/LV + BV-high	32	24	0.434	7.2	0.217	16.1	0.582
41	5-FU/LV	105	15	0.055	5.5	0.0002	12.9	0.16
	5-FU/LV + BV	104	26		9.2		16.6
43	FOLFOX	289	9	< 0.001	4.8	< 0.001	10.7	0.0018
	FOLFOX + BV	290	22		7.2		12.5
44	FOLFOX/bFOL/XELOX	147	22-43	NR	6.1-8.7	NR	18.2	NR
	FOLFOX/bFOL/XELOX + BV	213	41-53		8.3-10.3		24.4
45	FOLFOX/XELOX	701	49	0.99	8.5	< 0.001	-	-
	FOLFOX/XELOX + BV	699	47		11		-

CRC: Colorectal carcinoma; 5-FU/LV: 5-fluorouracil/leucovorin; IFL: Irinotecan/5-FU/leucovorin; FOLFOX-4: Oxaliplatin/5-FU/leucovorin; BV: Bevacizumab; Pts: Patients enrolled; REF: reference; RR: Response rate; PFS: Progression-free survival; TTP: Time to tumor progression; OS: Overall survival; NR: Not reported.